CSL traded at 272.73 this Wednesday May 25th, decreasing 1.42 or 0.52 percent since the previous trading session. Looking back, over the last four weeks, CSL lost 1.26 percent. Over the last 12 months, its price fell by 6.59 percent. Looking ahead, we forecast CSL to be priced at 268.18 by the end of this quarter and at 251.32 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
272.73
Daily Change
-0.52%
Yearly
-6.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
CSL 272.73 -1.42 -0.52% -6.59%

Indexes Price Day Year
AUALL 7392 18.50 0.25% 0.82%
AU50 6999 40.40 0.58% 1.84%
AU200 7155 26.40 0.37% 0.88%

CSL
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.